Faron Pharmaceuticals LTD: Holding(s) In Company

TURKU, FI / ACCESS Newswire / May 18, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an "X")An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify) iii: Decrease of holdings3. Details of person subject to the notification obligation ivNameBlood Cancer United, Inc.City and country of registered office (if applicable)Washington, D.C., United States of America4. Full name of shareholder(s) (if different from 3.) vName TAP BCU Faron, LLCCity and country of registered office (if applicable)Newark, Delaware, United States of America5. Date on which the threshold was crossed or reached vi:15/04/20266. Date on which issuer notified (DD/MM/YYYY):14/05/20267. Total positions of person(s) subject to the notification obligation% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) viiResulting situation on the date on which threshold was crossed or reached3.47%3.47%7,037,426Position of previous notification (ifapplicable)8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viiiA: Voting rights attached to sharesClass/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rightsDirect(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)FI40001533097,037,4263.47%SUBTOTAL 8. A7,037,4263.47%B 1: Financial Instruments according to DTR5.3.1R (1) (a)Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rightsSUBTOTAL 8. B 1B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rightsSUBTOTAL 8.B.29. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an "X")Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiiiFull chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivXName xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable thresholdBlood Cancer United, Inc. 100% owner of TAP BCU, LLC0%0%TAP BCU, LLC. 100% owner of TAP BCU Faron, LLC0%0%TAP BCU Faron, LLC,3.47%3.47%10. In case of proxy voting, please identify:Name of the proxy holderThe number and % of voting rights heldThe date until which the voting rights will be held11. Additional information xviProviding information directly to the Company as a result of meeting the threshold in the Company's Arti-cles of Association (does not meet the AIM regulatory notification threshold).Gordon G. Miller, Jr. ("JR Miller"), Executive Vice President & Chief Financial Officer Blood Cancer United, Inc. and authorized controlling person with respect to:Blood Cancer United, Inc., TAP BCU, LLC and TAP BCU Faron, LLCTAP BCU Faron, LLC, c/o Blood Cancer United, Inc. 1201 15th Street N.W., Suite 410, Washington, D.C. 20005 U.S.A.+1.860.488.1774Jr.Miller@bloodcancerunited.org3.47% of shares and voting rights is as per Faron Pharmaceuticals Ltd. request to include Treasury Shares in the denominator. The percentage is 3.527% if exclude Treasury Shares.Place of completionBlood Cancer United, Inc. Washington, D.C. U.S.A.Date of completion14/05/2026SOURCE: Faron PharmaceuticalsView the original press release on ACCESS Newswire

Raccontata damorningstar.com